Clinical trial
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With Type 2 Diabetes Mellitus
NCT06047262 is registered in ClinicalTrials.gov with Marc Donath as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- Marc Donath
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 9, 2024
- Completion date
- July 31, 2028
- Enrollment
- 300 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.